Your Health. Your Family. Your Choice.
|History of Changes from the VAERS Wayback Machine|
|Vaccination / Manufacturer||Lot / Dose||Site / Route|
|COVID19: COVID19 (COVID19 (PFIZER-BIONTECH)) / PFIZER/BIONTECH||- / UNK||- / -|
Administered by: Other Purchased by: ??
Life Threatening? No
Birth Defect? No
Permanent Disability? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Preexisting Conditions: Medical History/Concurrent Conditions: Emphysema; Lung cancer stage IV; Metastatic carcinoma
Diagnostic Lab Data:
CDC 'Split Type': JPPFIZER INC2021766910
Write-up: Death; This is a spontaneous report from a contactable physician received via a Pfizer sales representative. The patient was a 68-year-old male. Medical history included lung cancer stage IV, emphysema, and metastatic carcinoma. On an unspecified date (the day of vaccination), the patient received BNT162b2 (COMIRNATY, Solution for injection, Dose number, lot number, and expiration date were not reported) via an unspecified route of administration as a single dose for COVID-19 immunization. On an unspecified date (4 days after the vaccination), the patient experienced death. The outcome of the event was fatal. The course of the event was as follows: The patient had lung cancer stage IV but received COMIRNATY at the request of family member. Four days later, the patient died. It was not reported if an autopsy was performed. Seriousness criteria was not provided. The reporting physician assessed that the event was possibly related to BNT162b2. The reporting physician commented as follows: The condition of underlying disease was severe and causality between the event and the vaccination of COMIRNARY was considered less possibility.; Sender''s Comments: The causal relationship between BNT162b2 and the event death cannot be excluded as the information available in this report is limited and does not allow a medically meaningful assessment. The causal role of the pre-existing medical conditions of the patient cannot be excluded. This case will be reassessed once additional information becomes available. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees, and Investigators, as appropriate.; Reported Cause(s) of Death: Death
Copyright © 2021 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166